Louisiana State Employees Retirement System Takes Position in Xencor, Inc. $XNCR

Louisiana State Employees Retirement System purchased a new position in shares of Xencor, Inc. (NASDAQ:XNCR) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 31,700 shares of the biopharmaceutical company’s stock, valued at approximately $382,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Tower Research Capital LLC TRC boosted its stake in Xencor by 118.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 3,018 shares during the last quarter. E Fund Management Co. Ltd. bought a new stake in shares of Xencor in the 2nd quarter worth about $79,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Xencor in the 4th quarter valued at about $81,000. iSAM Funds UK Ltd acquired a new stake in shares of Xencor in the 2nd quarter valued at about $122,000. Finally, Prelude Capital Management LLC bought a new position in shares of Xencor during the third quarter worth about $139,000.

Analyst Upgrades and Downgrades

A number of research firms recently commented on XNCR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research note on Wednesday, June 24th. JPMorgan Chase & Co. upped their price objective on Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Monday, May 11th. Truist Financial reduced their target price on Xencor from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday. Zacks Research upgraded Xencor from a “strong sell” rating to a “hold” rating in a research report on Monday. Finally, Wall Street Zen downgraded Xencor from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $24.25.

Xencor Stock Up 5.0%

Shares of NASDAQ:XNCR opened at $16.46 on Thursday. The company has a market cap of $1.22 billion, a PE ratio of -7.19 and a beta of 0.86. Xencor, Inc. has a fifty-two week low of $6.92 and a fifty-two week high of $18.69. The firm has a 50-day simple moving average of $12.76 and a 200 day simple moving average of $12.77.

Xencor (NASDAQ:XNCR) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.96). Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The business had revenue of $4.52 million during the quarter, compared to the consensus estimate of $27.86 million. During the same period in the prior year, the business earned ($0.66) EPS. The business’s revenue was down 86.2% on a year-over-year basis. As a group, research analysts forecast that Xencor, Inc. will post -3.84 EPS for the current fiscal year.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.